We have previously explored the metabolism of B-amyloid precursor (APP) in a variety of cultured cells models and sought to produce insoluble Beta-amyloid deposits in cultured human neuronal cells. Mutations flanking the Beta-protein domain migrate with familial Alzheimer's Disease (FAD) supporting the hypothesis that accelerate B-amyloid deposition is sufficient to cause AD. APP670/671 mutations markedly accelerate B-protein production, but now FAD APP717 mutations effect APP and Beta-protein metabolism remains controversial; it may result in a greater percentage of longer forms of B-protein. Because it is a critical determinant in aggregation, we will investigate the C-terminus of secreted B. We are developing specific antibody probes to the C- terminus of B to explore this region in experiments with cultured cells with and without the APP717 mutations, and in AD and control CSF and brains available through the ADRC. Unfortunately, APP-like molecules of similar size are detected by many N-terminal APP antibodies and all C- terminal APP antibodies confusing results in most cultured cell systems even if transection are used. Hence, we are using CNS-derived neuroblastoma which lack detectable endogenous APP or APP-like cross- reacting molecules to examine the FAD APP mutations effects and APP metabolism. Secretion of B protein by cultured cells raise a number of issues concerning the metabolism of B-protein in vitro and the relationship of normal B-protein secretion to pathological B-protein deposition. We propose experiments to analyze the cellular pathway involved in B- production using a unique collection of processing mutants and treatment. Because B-degradation may be just as relevant to amyloidosis as production rates, we also design experiments to define the mechanism of B-degradation which is completely unknown. We have detected and propose to identify unknown proteins associated with APP, and may be involved in APP metabolism. Differences in the transport and metabolism of alternatively spliced APP are suggested from experiments with brain and CSF, but have not been shown in cultured cells. APP751, but not APP695 transgenics are reported to make diffuse B deposits. Thus, we also propose to look at B-protein and APP isoform metabolism in polarized APP transfected and parent NT2/D1 derived human neurons. These experiments should have a direct impact on understanding AD pathogenesis.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005131-15
Application #
6267252
Study Section
Project Start
1998-04-15
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Graves, Lisa V; Holden, Heather M; Van Etten, Emily J et al. (2018) New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease. J Int Neuropsychol Soc 24:833-841
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Fong, Lauren K; Yang, Max M; Dos Santos Chaves, Rodrigo et al. (2018) Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-? clearance in human astrocytes. J Biol Chem 293:11341-11357
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Spencer, Brian; Brüschweiler, Sven; Sealey-Cardona, Marco et al. (2018) Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol 136:69-87
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17

Showing the most recent 10 out of 914 publications